AstraZeneca to acquire Alexion for $39bn

This includes the company’s complement component 5 (C5) inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab), which are already available in the US and EU. ... AZ is also projecting that the acquisition will deliver double-digit average annual

Roche’s Soliris rival Enspryng bags FDA approval

Roche’s neuromyelitis optica spectrum disorder (NMOSD) drug Enspryng has scored US Food and Drug Administration (FDA) approval, setting up a market clash with Alexion’s Soliris. ... The first approved treatment in the US for NMOSD is Alexion’s

Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial

Shares shot up more than 50% in wake of announcement. Apellis has new data showing that its pegcetacoplan drug outperformed Alexion’s market leading Soliris in rare disease paroxysmal nocturnal haemoglobinuria ... with C5 inhibitor Soliris and

Roche’s Soliris rival satralizumab scores in phase 3 study

Alexion also received European Commission approval for the extended use of Soliris in the same indication in August. ... However, both Roche and Alexion could face competition from biosimilars, as Amgen  recently filed a patent infringement action

1 2 3 4 5 6 7 8 9 [ Next 5 results ]